Navigation Links
Grupo Casa Saba Announces 3Q09 Earnings Report
Date:10/28/2009

ed for 3.84% (versus 3.83% during the third quarter of 2008). Health, Beauty, Consumer Goods, General Merchandise and Other represented 8.49% (compared to 9.19% in the third quarter of 2008) and Publications made up the remaining 2.76% (versus 3.09% during the third quarter of 2008).

GROSS INCOME

During the third quarter of the year, Grupo Casa Saba's gross income increased 2.43% versus the same period of the previous year to reach $762.04 million. This growth was primarily driven by our Private Pharma division.

The company's gross margin was 10.87%, 26 basis points lower than the 11.13% margin posted during 3Q08. The margin was affected by an increase in the cost of sales resulting from less favorable commercial conditions with the main Brazilian wholesalers.

OPERATING EXPENSES

GCS's operating expenses reached $551.63 million in 3Q09, an increase of 6.52% compared to the third quarter of 2008. The increase in expenses continues to be related to our Brazilian operations.

Operating expenses represented 7.87% of our total sales in 3Q09 compared to 7.75% during the same period of the previous year.

OPERATING INCOME

Quarterly operating income was $210.41 million, 6.93% lower than the $226.07 reported in 3Q08. This decline was due to the fact that the growth in sales was not sufficient to offset the increase in operating expenses.

The operating margin was 3.00%, 38 basis points lower than the 3.38% margin registered in the third quarter of 2008.

OPERATING INCOME PLUS DEPRECIATION AND AMORTIZATION

Operating income plus depreciation and amortization for 3Q09 was $235.41 million, a decrease of 5.72% compared to the third quarter of 2008. Depreciation and amortization for the period was $25.00 million, 5.90% higher than in the third quarter of 2008.

CASH AND CASH EQUIVALENTS


'/>"/>
SOURCE Grupo Casa Saba
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
2. BioMarin Announces Third Quarter 2009 Financial Results
3. Rigel Announces Presentations at Two Investor Conferences
4. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
5. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
6. CardioGenics Holdings Inc. Announces Letter to Shareholders
7. Heska Announces Q309 Results
8. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
9. Inverness Medical Innovations Announces Third Quarter 2009 Results
10. Logical Therapeutics Announces Positive Results of LT-NS001 vs. Naproxen Clinical Study
11. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. ... (NASDAQ: SRNE ;  Sorrento), an oncology ... pain, and Conkwest, Inc., a privately-held immuno-oncology company ... Killer (NK) cell-line based therapy, announced today that ... to jointly develop next generation CAR-TNK™ (pronounced as ...
(Date:12/19/2014)... Somewhere between dropping five pounds and cooking ... Audicus , a next-generation hearing aids company, will ... Hearing loss is the third most common ... is often unaddressed. Forty-eight million Americans have hearing loss, ... mainly due to price. Hearing aids traditionally cost $7,000 ...
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Disease Market to 2017 - Patent ... as Aricept, Namenda, Avonex, Rebif and ...
... Leading events organiser UBM Live , a division ... a new event, CPhI South East Asia to cater to ... 10 to 12 May at the Jakarta International Expo in ... pharmaceutical events is being introduced to offer a meeting place ...
Cached Medicine Technology:Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15CPhI Global Portfolio Expands into South East Asia 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Coral Gables is ... service , Lice Troopers, with its new clinic location set ... Florida, takes the hassle out of dealing with this common ... one of their two salon clinic locations in South Florida, ... location. , The decision to expand developed naturally out of ...
(Date:12/22/2014)... International efforts to combat ... are receiving further support from recent initiatives ... (NGOs) and other charitable organizations. While research ... responders, patients and others can immediately benefit ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The MedTech industry ... Inc, a wholly owned subsidiary of PartnerTech AB of Sweden, ... having recently achieved additional ISO Certification. , All signs point ... employment and the likelihood of a repeal of the excise ... . The industry is anticipating annual growth of 9.3% and ...
(Date:12/22/2014)... Dallas, Texas (PRWEB) December 22, 2014 Luxury ... with Community Partners of Dallas to provide logistics ... A Dallas-based company, Peacock Alley has a long history of ... works. The additional sponsors of this year's Toy Drive were ... time to give back than the holidays. Providing gifts to ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... 03, 2007 - Gastroesophageal reflux disease (GERD), often known ... been associated with cancers, asthma, recurrent aspiration and pulmonary ... of Gastroenterology examines whether GERD sufferers may have shorter ... on over 50,000 person-years of data, the study provides ...
... CAMBRIDGE, Mass., Jan. 3, 2008 -- Psychologists at Harvard ... perception that, they argue, can resolve the century-old debate ... not only illustrates a new method for studying such ... against the existence of extrasensory perception, or ESP. , ...
... 23 million Americans age 12 or older need treatment for ... than 10 percent actually receive it. Worse, among those ... treatments that are known to work. , We have treatments ... Paul Roman, University of Georgia Distinguished Research Professor of Sociology ...
... VICTORIA, Jan. 3 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals,Corporation (NASDAQ: ... completion of the,plan of arrangement with Galenica Group ... Canadian subsidiary, acquired all,outstanding shares of Aspreva for ... completion of the plan of arrangement, Aspreva will ...
... Jan. 3 DaVita Inc. (NYSE:,DVA) announced today that ... January 7-11, 2008 at the Westin St. Francis Hotel ... will be presenting on,January 8, at 9:00 a.m. Pacific ... presentation will also be broadcast live and by replay. ...
... The Jeffrey Modell Foundation drives initiative for SCID screening, ... became the first,state in the nation to screen all ... "Bubble Boy Disease," SCID is a,genetic disorder that is ... referred for potentially life-saving treatment., The Wisconsin Department ...
Cached Medicine News:Health News:Researchers use neuroimaging to study ESP 2Health News:Researchers use neuroimaging to study ESP 3Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 2Health News:UGA researchers receive $9 million in grants to study barriers to effective addiction treatment 3Health News:Aspreva's plan of arrangement with Galenica completed 2Health News:Aspreva's plan of arrangement with Galenica completed 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 2Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 3Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 4Health News:Wisconsin First State in Nation to Screen Newborns for 'Bubble Boy Disease' 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: